CRISPR gene editing durably lowered blood lipid levels in trial

Results published in Nature show that CRISPR base editing targeting the ANGPTL3 gene, applied in vivo, can durably reduce blood lipid levels with a single genetic intervention. The study opens the path to new therapies for cardiovascular disease linked to elevated cholesterol and triglycerides.